HIV-1-infection
Conditions
Keywords
HIV-1
Brief summary
The study assesses PK and safety of other drugs, such as some antibiotics, proton pump inhibitors, statins, and combined oral contraceptives when co-administered with Elpida®
Detailed description
This study evaluates the drug-drug interaction of Elpida® and other drugs (Rifampin, Rifabutin, Clarithromycin, Omeprazole, Atorvastatin and combinations of Levonorgestrel and Ethinylestradiol) according to changes in the PK parameters of the study substances in their single co-administration in healthy subjects
Interventions
DRUGElpida®
Elpida® capsules, 20mg
DRUGRifampin
Rifampin capsules, 150mg
DRUGRifabutin
Rifabutin capsules, 150mg
DRUGClarithromycin
Clarithromycin Film-coated tablets, 250mg
DRUGOmeprazole
Omeprazole Film-coated tablets 20mg
DRUGAtorvastatin
Atorvastatin Film-coated tablets, 80mg
DRUGLevonorgestrel+Ethinylestradiol
Levonorgestrel 150 μg + Ethinylestradiol 30 μg, Film-coated tablets
Sponsors
Viriom
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
Healthy subjects must meet the following criteria to be enrolled in the study: 1. Non-smoking men and women between the ages of 18 and 45 years (inclusive) (only women in Group 7); 2. Verified healthy diagnosis according to standard clinical, laboratory and instrumental examination methods; 3. Body Mass Index ranges between 18.5 kg/m2 and 30.0 kg/m2 and a body weight NLT 50 kg; 4. Negative alcohol and drug tests; 5. Consent to use two adequate and reliable methods of contraception throughout the study and up to 3 months after its completion: a condom with spermicide (foam, gel, cream, suppositories), or a diaphragm with spermicide, or a condom and diaphragm, or a condom and an intrauterine device; 6. Signed Patient Information Sheet and form of Informed Consent to participate in the study.
Exclusion criteria
A subject will be considered not eligible to participate in the study if one or more of the following criteria is met: 1. Chronic diseases of cardiovascular, bronchopulmonary, neuroendocrine, musculoskeletal system, as well as diseases of the gastrointestinal tract, liver, kidneys, blood; 2. Variables of standard laboratory and instrumental parameters are beyond the normal limits (taking into account the acceptable limits of laboratory parameters; 3. Surgical interventions on the gastrointestinal tract in medical history (except appendectomy); 4. Systolic pressure below 90 mm Mercury or above 130 mm Mercury, diastolic pressure below 60 mm Mercury or above 85 mm Mercury, heart rate less than 60 BPM or more than 90 BPM at screening; 5. Regular intake of drugs less than 2 weeks prior to screening (including herbal preparations and dietary supplements); intake of drugs that have a pronounced effect on hemodynamics, hepatic function, etc. (for example, barbiturates, omeprazole, cimetidine, etc.) less than 30 days prior to screening; 6. Presence of antibodies to HIV and hepatitis C virus, presence of hepatitis В surface antigen, a positive syphilis test; 7. An unstable sleep structure (e.g., night work, sleep disorders, insomnia, recent return from another time zone, etc.), extreme physical activity (e.g. weight lifting), a special diet (e.g. vegetarian, vegan); 8. Signs of alcohol (intake of more than 10 units of alcohol per week) or drug addiction; alcohol or drugs consumption within 4 days prior to screening; cigarettes smoking 3 months prior to screening; positive drug and/or alcohol test; 9. Drug allergies in medical history (including drug intolerance, including hypersensitivity to any components of study drugs) as well as food allergy; 10. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption; 11. Individual intolerance to any components of study drugs; 12. Blood/plasma donation (450 ml of blood or plasma and more) less than 2 months prior to screening; 13. Treatment with a study drug in framework of other clinical trials within 1 month prior to screening (including follow-up visits); 14. Acute infectious diseases less than 4 weeks prior to screening; 15. Inhibitors or inducers of CYP3A4/5, drugs that cause QT prolongation within 30 days prior to StD administration; 16. For women - positive result of pregnancy test or breastfeeding; Inability to read or write; unwillingness to understand and adhere to the study protocol procedures; non-compliance with the drugs intake regimen or execution of procedures, which as the Investigator believes may affect the study results or subject's safety and prevent the subject from further participation in the study; any other associated medical or serious psychological conditions making the subject not eligible to participate in the clinical study, restricting legality of obtaining the Informed Consent or affecting the subject's ability to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma concentration of ethinylestradiol | 42 days |
| Plasma concentration of elsulfavirine | 42 days |
| Plasma concentration of VM1500A | 42 days |
| Plasma concentration of rifampicin | 42 days |
| Plasma concentration of rifabutin | 49 days |
| Plasma concentration of clarithromycin | 42 days |
| Plasma concentration of atorvastatin | 42 days |
| Plasma concentration of levonorgestrel | 42 days |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of AEs and SAEs | 49 days |
Countries
Russia
Outcome results
None listed